Skip to content

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
1.4×+0.2×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
5.6×+1.6×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
1.9×+0.4×
Beam Therapeutics logo
Beam TherapeuticsBEAM
3.9×+0.1×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
0.6×+0.3×

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Calculated from Disc Medicine’s reported figures.

Based on the most recent quarter.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's cash ratio?
Disc Medicine (IRON) reported cash ratio of 2.9× in Q1 2026.
How has Disc Medicine's cash ratio changed year-over-year?
Disc Medicine's cash ratio decreased by 56.4% year-over-year, from 6.5× to 2.9×.
What is the long-term trend for Disc Medicine's cash ratio?
Over 5 years (2020 to 2025), Disc Medicine's cash ratio has grown at a 68.9% compound annual growth rate (CAGR), from 0.2× to 2.5×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.